U.S. Markets closed

SmallCap Sentinel: Courting Colombian Cannabis

ORLANDO, FL / ACCESSWIRE / January 9, 2019 / The explosion of the cannabis and hemp market in the United States is no secret to investors. Stocks related to these industries have been among some of the most followed in the market as the watershed events of massive legislative chan ges and an exponentially expanding consumer market for recreational and medicinal cannabis is unprecedented. Today's featured company Digipath Inc. (DIGP) is well-positioned at the intersection of this opportunity with big plans to leverage its domestic successes in an enormous new market.

Many tend to liken the beneficial legislative changes for marijuana to the End of Prohibition and the subsequent massive return of alcohol sales. At SmallCap Sentinel we believe that is a narrow view.

The recently passed Farm Bill literally liberates the national sale of hemp (and financing for hemp) and will be absolutely catalytic to the introduction of CBD in an unlimited amount of products. CBD, the non-psychoactive element of cannabis found in hemp, is already being mixed into cosmetics, food, water, creams, and more. So while the removal of laws that disallowed recreational use can be compared to the End of Prohibition, the national allowance of hemp production will now be similar to something like the introduction of plastic in the 1940s or even grocery refrigeration, a movement that will essentially change and impact an enormous amount of products. You will begin to see CBD most everywhere. (Editor's note: try this must read from Forbeson the Farm Bill and the Future of Hemp.)

Digipath has staked its claim in the market as one of the premier cannabis testing laboratories in the world. In nearly every market where cannabis or hemp is allowed in any capacity strict laws and quality control are required. Digipath is an absolute technology leader in creating the highest standard of testing and accountability, established primarily in the vast Nevada marijuana and hemp market. Digipath holds the top levels of testing accreditation and its Chief Science Officer, Cindy Orser is renowned as an expert in the industry, helping to create the standards that will allow for research, discovery, and new products to occur.

What is intriguing about Digipath is its stated intentions to leverage its pedigree here in the U.S. and pursue larger and greener pastures in larger international markets like Colombia in South America. Colombia is believed by many to soon be one of the top producers of cannabis due to its favorable climate, environment and strong government support.

If Digipath can create operational successes in Colombia – and other massive foreign markets- it could be a game-changer for the established Las Vegas based laboratory. Certainly, Digipath has the pedigree and proven business model to pursue these lucrative interests.

For an Investor's Introduction to Digipath please visit https://bit.ly/2ALNzRR

About Digipath, Inc. & Digipath Labs, Inc.

Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.

About SmallCap Sentinel:

SmallCap Sentinel is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

EMC has been paid $10,000 dollars by Digipath for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. A contributor to this report holds 400,000 shares and receives $3,500 a month for a period of six months for investor relations services on the behalf of Digipath.

http://emergingmarketsllc.com/disclaimer.php

Emerging Markets Consulting, LLC

E-mail: jamespainter@emergingmarketsllc.com

Web: www.emergingmarketsllc.com

SOURCE: SmallCap Sentinel